Common Stock, par value $0.001
- Symbol
- BMRN
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K/A
BioMarin Pharmaceutical Inc.
BMRNNASDAQEQUITYCurrent
Other Events
Item 9.01 Financial Statements and Exhibits. (a) Financial Statements of Businesses Acquired. The audited financial statements of Amicus as of December 31, 2025 and 2024 and for the years ended December 31, 2025, 2024, and 2023 are filed herewith as Exhibit 99.1 and incorporated by reference into this Item 9.01 (a). The consent of Ernst & Young LLP, Amicus' independent auditor, is filed herewith as Exhibit 23.1.…
Company context
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
Current securities
Recent company filings
Registered securities in this filing
BioMarin Pharmaceutical Inc. · 8-K/A · Filed 2026-07-13
Disclosure sections
Item 9.01Item 9.01 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired.
The audited financial statements of Amicus as of December 31, 2025 and 2024 and for the years ended December 31, 2025, 2024, and 2023 are filed herewith as Exhibit 99.1 and incorporated by reference into this Item 9.01 (a). The consent of Ernst & Young LLP, Amicus' independent auditor, is filed herewith as Exhibit 23.1.
(b) Pro Forma Financial Information.
The unaudited pro forma condensed combined balance sheet as of December 31, 2025, the unaudited pro forma condensed combined statements of operations for the year ended December 31, 2025, and the notes to the unaudited pro forma condensed combined financial information of the Company, all giving effect to the Acquisition are filed herewith as Exhibit 99.2 and incorporated herein by reference into this Item 9.01(b).
(d) Exhibits.
Exhibit Number Description
───────────────────────────────────
23.1 Consent of Ernst & Young LLP, Amicus Therapeutics, Inc.'s Independent Auditor
99.1 The audited financial statements of Amicus as of December 31, 2025 and 2024 and for the years ended December 31, 2025, 2024, and 2023.
99.2 Unaudited Pro Forma Condensed Combined Financial Information.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
Filed exhibits (2)
EX-99.1 3 ex991-amicusauditedfinanci.htm EX-99.1 - UNAUDITED FINANCIAL STATEMENTS Document Exhibit 99.1 Report of Independent Registered Public Accounting Firm To the Stockholders and the Board of Directors of Amicus Therapeutics, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Amicus Therapeutics, Inc. (the Company) as of December 31, 2025 and 2024, the related consolidated statements of operations, comprehensive loss, changes in stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with U.S. generally accepted accounting principles. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Co…
Open exhibit ↗EX-99.2 4 ex992-unauditedproformafin.htm EX-99.2 - PRO FORMA FINANCIAL STATEMENTS Document EXHIBIT 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On April 27, 2026, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) completed its previously announced acquisition of all of the issued and outstanding shares of capital stock of Amicus Therapeutics, Inc. (“Amicus”) (the “Merger”). The Merger was completed pursuant to an Agreement and Plan of Merger (the “Agreement”) entered into on December 19, 2025. The unaudited pro forma condensed combined balance sheet as of December 31, 2025 combines the historical consolidated balance sheets of BioMarin and Amicus, giving effect to the Transactions (as defined below), as if they had occurred on December 31, 2025. The unaudited pro forma condensed combined statement of operations for the fiscal year ended December 31, 2025 combines the historical consolidated statements of operations of BioMarin and Amicus, giving effect to the Transactions, as if they had occurred on January 1, 2025. The pro forma condensed combined financial information reflects the following transactions (the “Transactions”): a) Amicus’ stock…
Open exhibit ↗